|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2001-11-15
|
|
pubmed:abstractText |
Genotype data for CCR5, CCR2, and stromal cell-derived factor 1 (SDF-1) were obtained from 354 human immunodeficiency virus type 1 (HIV-1)-positive subjects who were being treated with nucleosides. Associations with HIV-1 load, HIV syncytium-inducing (SI) phenotype, CD4 cell count, and disease progression were analyzed. No differences in HIV-1 load or CD4 cell count were observed between wild type (+) and variant genotypes. Changes from non-SI to SI viral phenotype were more frequent in heterozygotes with a 32-bp deletion (Delta32) in the CCR5 gene than in + homozygotes (40% vs. 7%; P=.01). In a multivariate analysis, heterozygous CCR5 Delta32 was associated with reduced hazard of progression (hazard ratio, 0.32; P=.02). Subjects homozygous for the SDF-1 3'A variant had more-rapid disease progression (P=.008). The SDF-1 homozygous 3'A variant was related to more-rapid disease progression, and CCR5 Delta32 was associated with reduced rates of hazard for disease progression in nucleoside-treated subjects.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents,
http://linkedlifedata.com/resource/pubmed/chemical/CCR2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CXCL12 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokine CXCL12,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokines, CXC,
http://linkedlifedata.com/resource/pubmed/chemical/Nucleosides,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CCR2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CCR5,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Chemokine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
pubmed-author:AlexanderH CHC,
pubmed-author:BarrogaC FCF,
pubmed-author:BettendorfD MDM,
pubmed-author:ChangS YSY,
pubmed-author:D'AquilaR TRT,
pubmed-author:HammerS MSM,
pubmed-author:HughesA MAM,
pubmed-author:KatzensteinD ADA,
pubmed-author:LanderJ DJD,
pubmed-author:LatheyJ LJL,
pubmed-author:SantiniC DCD,
pubmed-author:SpectorS ASA,
pubmed-author:TierneyCC
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
184
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1402-11
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11709782-Adult,
pubmed-meshheading:11709782-Anti-HIV Agents,
pubmed-meshheading:11709782-CD4 Lymphocyte Count,
pubmed-meshheading:11709782-Chemokine CXCL12,
pubmed-meshheading:11709782-Chemokines, CXC,
pubmed-meshheading:11709782-Disease Progression,
pubmed-meshheading:11709782-Disease-Free Survival,
pubmed-meshheading:11709782-Double-Blind Method,
pubmed-meshheading:11709782-Female,
pubmed-meshheading:11709782-Genotype,
pubmed-meshheading:11709782-Giant Cells,
pubmed-meshheading:11709782-HIV Infections,
pubmed-meshheading:11709782-HIV-1,
pubmed-meshheading:11709782-Humans,
pubmed-meshheading:11709782-Leukocytes, Mononuclear,
pubmed-meshheading:11709782-Male,
pubmed-meshheading:11709782-Nucleosides,
pubmed-meshheading:11709782-RNA, Viral,
pubmed-meshheading:11709782-Receptors, CCR2,
pubmed-meshheading:11709782-Receptors, CCR5,
pubmed-meshheading:11709782-Receptors, Chemokine,
pubmed-meshheading:11709782-Viral Load
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.
|
|
pubmed:affiliation |
Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA. jlathey@zycos.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Multicenter Study
|
